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Abstract
Background: The purpose of this clinical study is to investigate the clinical feasibility and effectiveness of offline
Positron-Emission-Tomography (PET) quality assurance for promoting the accuracy of proton and carbon ion beam
therapy.
Methods/Design: A total of 240 patients will be recruited, evenly sampled among different analysis groups
including tumors of the brain, skull base, head and neck region, upper gastrointestinal tract including the liver,
lower gastrointestinal tract, prostate and pelvic region. From the comparison of the measured activity with the
planned dose and its corresponding simulated activity distribution, conclusions on the delivered treatment will be
inferred and, in case of significant deviations, correction strategies will be elaborated.
Discussion: The investigated patients are expected to benefit from this study, since in case of detected deviations
between planned and actual treatment delivery a proper intervention (e.g., correction) could be performed in a
subsequent irradiation fraction. In this way, an overall better treatment could be achieved than without any in-vivo
verification. Moreover, site-specific patient-population information on the precision of the ion range at HIT might
enable improvement of the CT-range calibration curve as well as safe reduction of the treatment margins to
promote enhanced treatment plan conformality and dose escalation for full clinical exploitation of the promises of
ion beam therapy.
Trial Registration: NCT01528670
Background
In comparison to conventional external beam radiotherapy
with photon and electron radiation, ion therapy may offer
superior conformation of the dose delivery to the tumour,
with improved sparing of the surrounding healthy tissue
and critical organs. This is mainly due to the favourable
energy deposition, which can be concentrated in a few
millimeters narrow region (the Bragg-peak) at an adjusta-
ble depth [1]. However, exploitation of this selectivity to
its full extent in the clinical practice is still hampered by
uncertainties in the knowledge of the beam range in the
patient, resulting in the usage of generous safety margins
as well as avoidance of beam portals stopping directly in
front of critical organs. In fact, the complete stopping of
the primary ion beam in the patient prevents the applic-
ability of conventional quality assurance techniques like
electronic portal imaging [2], which are well established in
clinical radiotherapy practice with photon radiation.
Hence, treatment planning algorithms can only be based
on models and data which are accurately validated in
tissue-equivalent phantoms [3,4], but no direct in-vivo
verification within the patient is currently feasible.
Nowadays, Positron-Emission-Tomography (PET)
offers the only technically feasible method for an indir-
ect three-dimensional (3D), in-vivo, non-invasive verifi-
cation of ion treatment during or shortly after
irradiation [5-11]. The method is based on the detec-
tion of the transient b
+-activity which is formed as a
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any medium, provided the original work is properly cited.by-product of the therapeutic irradiation (i.e., without
administering any radio-tracer to the patient) in
nuclear reactions between the incoming ions and the
target nuclei of the irradiated tissue. By correlating the
measured activity with the planned treatment and the
actual patient anatomy as given by a computed tomo-
gram (CT), it is possible to infer valuable information
on the actual dose delivery. As activity and dose are
different physical quantities, an additional comparison
of the acquired PET images with a corresponding acti-
vation pattern deduced from the planned treatment
and the specific time course of irradiation and imaging
is strongly recommended [6,11]. This expectation can
be obtained from a detailed Monte Carlo calculation of
the ion beam transport and interaction within the
patient [6,12-14], combined with the estimation of the
fraction of activity carried away from the place of pro-
duction by physiological processes such as perfusion,
generally referred to as “biological washout” [6].
The technical implementation of PET monitoring can be
performed using dedicated (typically limited angle) instru-
mentation directly located at the treatment site for in-
beam [11] or in-room [8] acquisition, or using commercial
nuclear medicine PET and PET/CT scanners installed clo-
seby to the treatment unit for offline imaging [6,7,9,10]. In
all cases, up-to-date anatomical information of the patient
can be obtained from control CTs (cone-beam or full-ring
scanner) which are acquired in regular intervals as a stan-
dard of care to evaluate correct patient positioning or to
detect any anatomical changes during the course of the
fractionated treatment in particle therapy. Therefore, no
additional CT-imaging is required for correlation with
PET measurements; however, when an additional CT is
available, anatomical changes may be monitored and
detected.
Promising experience in PET imaging of proton and car-
bon ion therapy has been so far obtained for more than 50
patients monitored after passive proton treatments in USA
and Japan, as well as more than 400 patients monitored
during scanned carbon ion beam irradiation at GSI Darm-
stadt, Germany [5-11]. In particular, the GSI pilot project
demonstrated the value of PET for improving the accuracy
of the semi-empirical CT-range calibration curve
employed by the treatment planning system as well as for
detecting and quantifying deviations between planned and
actual treatment delivery due to patient misalignments or
anatomical changes over the course of fractionated therapy
[5,11,15]. Therefore, this clinical experience clearly indi-
cates the potential value of the method especially in the
starting phase of a new facility such as the Heidelberger
Ionenstrahl Therapiezentrum (HIT) [16]. For this purpose,
a commercial PET/CT scanner has been installed at HIT
in a dedicated room closeby to the treatment area. How-
ever, the results from different therapy facilities cannot be
directly translated to the HIT center due to the differences
in the clinical protocol (fraction dose, number of portals),
ion species (p,
12C), beam-delivery system (passive scatter-
ing or active pencil-beam scanning), detector properties
(full-ring or limited angle PET scanner, detection technol-
ogy), imaging protocol (in-beam, in-room or off-beam
data acquisition [17]), as well as the limited number of the
so far investigated tumor types and sites. Therefore, a pilot
clinical study is needed at HIT in order to identify the
patient population which may benefit from PET imaging,
as well as extract population-based information on the
reliability of the delivered beam range for the available ion
species in different tumour locations.
In the proposed clinical study MIRANDA (Monitoring
of Patients treated with Particle Therapy using Positron-
Emission-Tomography) patient selection will be particu-
l a r l ya d d r e s s e dt ot h o s em o r ec r u c i a ls i t u a t i o n sw h e r e
utmost precision in the delivery of the planned dose with
optimal sparing of the surrounding critical structures is
mandatory. Especially in those cases where the ions have
to penetrate highly inhomogeneous tissue, the precision
of the intended dose deposition can be severely under-
mined by uncertainties of the treatment planning algo-
rithms and minor positioning errors. Thus, the proposed
PET method might offer a useful tool for assessing
unpredictable deviations between planned and actual
treatment. Moreover, PET-based verification might be
beneficial for patients having metallic implants, where
known shortcomings of the treatment planning algo-
rithms in combination with artifacts of the CT-based
patient model are of major dosimetric concern in ion
beam therapy [18].
The participating patients are expected to benefit from
this study, as in the eventuality of detected discrepancies a
timely intervention could be undertaken, thus guarantee-
ing an improved treatment quality than without PET
monitoring. Moreover, site-specific patient-population
information on the ion range precision at HIT might
enable in-vivo validation of the CT-range calibration curve
as well as safe reduction of the treatment margins to pro-
mote enhanced treatment plan conformality for full clini-
cal exploitation of the ballistic selectivity offered by ion
beam therapy.
Methods and Design
Aims of the Study
The purpose of this clinical study is to investigate the
clinical feasibility and effective benefit of off-line PET
for quality assurance of scanned proton and carbon ion
beam therapy for a large patient population.
The specific aims are to
1) Acquire PET/CT scan data on patients under-
going external beam ion therapy for a representative
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able to conclude which patients might in future ben-
efit from PET/CT monitoring.
2) Analyze these data to determine the accuracy with
which the beam range can be monitored and the
actually delivered dose can be estimated.
3) Analyze these data (acquired during at least three
fractions at the beginning, the middle and the end of
the regular treatment course) to determine whether
quantitative changes of the PET signal after delivery
of the same treatment fraction dose can be indica-
tors of physiological modifications connected to
tumour response.
4) Assess the possibility of using PET/CT monitor-
ing for quality assurance and adaptive strategies in
scanned ion beam therapy.
Procedure to be evaluated
The PET/CT scanner to be used is a CE-labelled medical
product (Siemens Biograph mCT 40). The procedure will
include acquisition of a control CT for anatomical refer-
ence as well as list-mode detection of the b
+-activity
resulting from the standard therapeutic irradiation. The
CT scan is performed for patient position verification as
well as monitoring of anatomical changes during the
course of radiotherapy and is considered standard of care.
Therefore, no trial specific CT imaging will be acquired
and patients will not be exposed to additional experimen-
tal doses of ionizing radiation. The PET signal to be mea-
sured is a by-product of the therapeutic ion beam
irradiation, hence no additional radioactive tracer is admi-
nistered to the patient. The treatment position will be
reproduced at the PET/CT scanner using the same immo-
bilization equipment used for the therapeutic irradiation,
which is compatible with standard diagnostic CT and PET
imaging.
The activity levels to be expected in the study are orders
of magnitude lower than in the typical operation condition
of the commercial PET device, which is designed for appli-
cation to nuclear medicine tracer imaging. Therefore, the
PET data acquisition will be performed in one single bed
position and last over 30 minutes to collect sufficient
counting statistics for imaging, following the same clinical
protocol reported by other investigators in previous clini-
cal trials in USA [6,10]. After the first clinical data will be
collected, the available iterative reconstruction schemes of
the PET scanner will be applied and the resulting images
will be compared in order to identify the optimal image
reconstruction settings for optimal imaging performances
at the expected low statistics levels. The so identified opti-
mal image reconstruction settings will be applied to pro-
cess all the clinical data acquired in this study.
The reconstructed PET images co-registered to the
control CT (using the CE-labelled software provided by
the manufacturer) will be finally analysed in comparison
to the planned treatment to infer information on the
correctness of the actually delivered therapeutic irradia-
tion. An additional comparison with an expected b
+-
activity distribution will be pursued [19].
Therapeutic and Diagnostic Modes of Action
By taking part in the MIRANDA study patients are
offered the possibility to determine the applied dose
more precisely, since by using the PET/CT for monitor-
ing the activation produced by the particle beam can be
visualized. The potential benefit for the future of radio-
therapy is to implement PET/CT in clinical routine for
dose monitoring possibly providing a useful tool for
necessary corrections in treatment planning or patient
positioning (adaptive particle therapy).
Side effects and risks as well as potential additional
exposures during study treatment
The b
+-activity is induced by the therapeutic irradiation;
therefore, no additional exposure of the patient is
required for the PET measurements. To carry out the
investigation with accurate anatomical co-registration,
this study is performed using a PET/CT. The additional
control CT enables the researchers to explore also ana-
tomical modifications compared to the initial imaging
data acquired for treatment planning. These control
CTs are performed on a regular basis during the course
of precision radiotherapy for verification of patient posi-
tioning and to monitor any anatomical changes to the
tumor and to normal tissue. Therefore, these CT scans
can be considered standard of care, and patients will not
be exposed to any additional ionizing radiation.
This study will cause the prolongation of the selected
treatment sessions, because of the time needed for the
transport of the patient to the remote PET/CT scanner
(about 5 min) and for the PET/CT acquisition (about 30
min). The latter is mainly determined by the required 30
minutes of PET acquisition, being the CT imaging typi-
cally completed in less than 1 min.
Study Design
Open, mono-centric, non-randomized, prospective study
to evaluate PET-CT monitoring after particle therapy
for position verification, dose deposition monitoring and
for the implementation of adaptive strategies for particle
therapy
Inclusion Criteria
￿ The patient is treated at the Heidelberger Ionenstrahl
Therapiezentrum (HIT) with protons or carbon ions.
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tioning and anatomy is verified using validated radiolo-
gical imaging such as cone beam CT, X-ray or
conventional CT (Reference-Imaging as described
above).
￿ The patient is at least 18 years of age and is able to
give informed consent.
￿ The patient has been informed about the aims and
the content of the study.
Within the study protocol, no additional radiological
imaging techniques will be performed. Therefore, the
patient will not be exposed to any additional irradiation.
Exclusion Criteria
￿ No informed consent to take part in the study.
￿ Medical reasons that impair the patients from being
in the supine position for the data acquisition time, e.g.
pain.
￿ Non-compliance of the patient.
Study plan
A patient fulfilling the inclusion criteria will be informed
about the background of this study and will be offered par-
ticipation. Thereafter, an information brochure about the
study will be handed out to the patient, and the patients
will be instructed about the study plan and procedures.
Thereafter, the patient can give informed consent. This
informed consent will be documented in a written form
(signature on informed consent form).
After the patient has given informed consent, patients
are included into the study. The study will include pro-
cedures as follows:
a. Right after a regular treatment fraction the patient
will be transferred to the PET/CT scanner located on
the same floor within few meters distance from the
treatment sites in the HIT building.
b. A PET/CT scan will be taken. For this examination
the patient will remain fixated in the immobilization
device used during treatment delivery. The average
acquisition time will be in the order of 30 minutes.
The procedure will be repeated for a total of at least
three treatment fractions, one being selected in the first
week of treatment, one in the middle of the treatment
period and one during the last week of therapy.
The study will cause prolongation of the selected
treatment sessions due to the transport to the remote
PET/CT scanner (about 5 min) and the PET/CT acqui-
sition (about 30 min). All subsequent data analysis will
be performed without interaction with the patient.
The data will be pseudonymized and analysed.
Concomitant treatment
No concomitant treatment is part of the study
protocol.
Criteria for withdrawal
Individual criteria
￿ Pain in supine position
￿ Agitated or restless patient
￿ Discontinuation of study participation by the patient
General withdrawal criteria for the study
There are no general withdrawal criteria for the study
protocol
Statistical Design
Feasibility and value of post-radiation PET imaging for
verification of therapeutic ion beam delivery should be
validated for different organ regions. Therefore, different
analysis groups will be evaluated including tumors of the
brain, skull base, head and neck region, upper gastroin-
testinal tract (upper GI), lower gastrointestinal tract
(lower GI), prostate and pelvic region. For optimal calcu-
lations and verification, 30 patients per anatomic region
will be analyzed. This amounts to a total patient number
of 240 patients.
After acquisition of the data, correlation of the measured
activity with the acquired CT imaging for patient position
and anatomy will be performed. Additionally, correlation
with the calculated dose plan within the Siemens Treat-
ment Planning System (TPS) will be performed. Potential
correction vectors consisting of positional changes will be
determined based on the newly acquired activity images
and the imaging that had been done for treatment
planning.
Correlation of the measured activity level with the
applied dose and pattern of RBE-values (relative biologi-
cal effectiveness) determined during the biological treat-
ment planning for particle therapy will be performed.
As activity and dose are known to be different physical
quantities, an additional calculation of the expected b
+-activity distribution will be pursued, provided that the
computational tool used for this purpose is verified to
deliver a corresponding calculation of dose distribution
in agreement with the certified clinical TPS.
To assess whether the calculated dose and activity dis-
tribution are different from the measured activity corre-
sponding to the applied dose distribution, a t-test as a
one-sample location test can be used („is the difference
different from zero”).
Ethical and legal aspects
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation, and documentation of this
trial, are designed to ensure that all persons involved in
the trial follow the guidelines of Good Clinical Practice
(GCP) and the ethical principles described in the applic-
able version of the Declaration of Helsinki (2008 Version
of the Declaration of Helsinki, adopted at the 59th WMA
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accordance with the “Berufsordnung für Ärztinnen und
Ärzte der Landesärztekammer Baden-Württemberg” in
the most recent version.
The trial will be carried out in adhering to local legal
and regulatory requirements.
The study plan was submitted to the Institutional
Review Board (IRB)/independent Ethics Committee (EC)
of the Medical Faculty Heidelberg, and official approval
was obtained.
Participation of a patient in this study is voluntary. A
subject may voluntarily discontinue participation in this
study at any time at their own request. Before study
entry, patients will be informed by the written informa-
tion brochure as well as in orally about the planned pro-
cedures within this study, especially about potential
benefit for their health or potential risks. Informed con-
sent will be documented by the patient’ss i g n a t u r eo n
the informed consent form.
All patients will be informed prior to initiation of study
treatment concerning the aims of the study, especially
with respect to any risks or side effects of the treatment,
as well as the potential use of study participation for the
overall treatment course. Informed consent will be docu-
mented as written informed consent by signature on the
informed consent sheet. If the subject withdraws from the
trial and also withdraws consent for disclosure of future
information, no further evaluations should be performed,
and no additional data should be collected. In all cases, the
reason for withdrawal must be recorded. In case of with-
drawal of a subject at his/her own request, the reason
should be asked for as extensively as possible and docu-
mented. All data acquired within this study will be deleted,
except if the patients allows for further evaluation of the
data and inclusion into the final analysis.
T h ed a t ao b t a i n e di nt h ec o u r s eo ft h et r i a lw i l lb e
treated pursuant to the Federal Data Protection Law
(Bundesdatenschutz- bzw. Landesdatenschutzgesetz,
BDSG, LDSG).
Trial findings stored on a computer will be stored in
accordance with local data protection law and will be
handled in strictest confidence. For protection of these
data, organizational procedures are implemented to pre-
vent distribution of data to unauthorized persons. The
appropriate regulations of local data legislation will be ful-
filled in its entirety.
No third party will have access to the patient data.
Discussion
An example of the first post-radiation PET/CT imaging
of a patient undergoing a scanned carbon ion boost
treatment of a glioblastoma tumour at HIT is illustrated
in Figure 1 [20]. After completion of a therapeutic treat-
ment fraction (3 GyE), the patient was walked to the
PET/CT scanner and immobilised using the same equip-
ment as for therapy. The 30 min PET acquisition could
be started about 8 min after single-field irradiation. The
depicted data refer to the prescribed dose from the
planning system (top) and the merged PET/CT images
(bottom). Despite the noise of the low-statistics PET
images, a promising correlation between the detected
activation and the planned dose is observed. In particu-
lar, this first clinical case strongly supports the possibi-
lity to visualize the delivered treatment and to confirm
in-vivo the planned ion range. Nevertheless, a more
detailed quantitative analysis as well as the additional
comparison with the expected pattern of induced activ-
ity is underway and will be separately reported [19,21].
From the encouraging initial results, it can be
expected that the proposed MIRANDA clinical study
will enable quantitative assessment of the feasibility and
value of offline PET-based in-vivo treatment verification
for promoting high precision ion beam therapy at HIT
for different treatment sites and ion species.
Figure 1 Patient undergoing a PET/CT measurement after
scanned ion irradiation at HIT. The patient was treated for a
primary brain tumour with a carbon ion boost. The top panel
depicts the dose planned by the commercial TPS overlaid onto the
planning CT in axial and sagittal views. The bottom panel depicts
the PET image acquired ca. 8 minutes after irradiation and overlaid
onto the control CT data, merged and visualised approximately in
the same views as the top raw.
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